Search results for " arthritis"

showing 10 items of 629 documents

Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3.

2016

Granulomatosis with polyangiitis (GPA) is a severe autoimmune disease and one of the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Although its etiology and pathophysiology are still widely unknown, it is accepted that infections, environmental factors, epigenetic modifications, and a genetic predisposition provide the basis for this systemic disorder. GPA typically evolves into two phases: an initial phase characterized by ear, nose and throat (ENT) manifestations, such as chronic sinusitis and otitis, ulceration of the oral cavity and pharynx, as well as pulmonary nodules and a severe generalized phase, defined by the occurrence of rapidly progressive g…

0301 basic medicineCandidate geneMyeloblastinGenome-wide association studyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitismacromolecular substancesBiologyAutoantigensAntibodies Antineutrophil CytoplasmicPTPN2203 medical and health sciencesMice0302 clinical medicinestomatognathic systemProteinase 3medicineGenetic predispositionRapidly progressive glomerulonephritisAnimalsHumansGenetic Predisposition to DiseaseMolecular Biology030203 arthritis & rheumatologyAutoimmune diseaseGranulomatosis with PolyangiitisCell Biologymedicine.disease030104 developmental biologyImmunologyGranulomatosis with polyangiitisGenome-Wide Association StudyMolecular and cellular probes
researchProduct

Gene therapy for chondral and osteochondral regeneration: is the future now?

2017

Gene therapy might represent a promising strategy for chondral and osteochondral defects repair by balancing the management of temporary joint mechanical incompetence with altered metabolic and inflammatory homeostasis. This review analysed preclinical and clinical studies on gene therapy for the repair of articular cartilage defects performed over the last 10 years, focussing on expression vectors (non-viral and viral), type of genes delivered and gene therapy procedures (direct or indirect). Plasmids (non-viral expression vectors) and adenovirus (viral vectors) were the most employed vectors in preclinical studies. Genes delivered encoded mainly for growth factors, followed by transcripti…

0301 basic medicineCartilage ArticularExpression vectorPathologymedicine.medical_specialtyCell signalingCartilage repair; Expression vectors; Gene therapy procedures; Osteoarthritis; Regenerative medicine; Molecular Medicine; Molecular Biology; Pharmacology; Cellular and Molecular Neuroscience; Cell BiologyBone RegenerationInflammatory arthritisGenetic enhancementGene therapy procedureOsteoarthritisViral vector03 medical and health sciencesCellular and Molecular NeuroscienceCartilage repairChondrocytesInterferonSettore BIO/13 - Biologia ApplicataOsteoarthritismedicineAnimalsHumansRegenerationMolecular BiologyPharmacologyExpression vectorbusiness.industryRegeneration (biology)Cell BiologyGenetic Therapymedicine.disease030104 developmental biologyRegenerative medicineCancer researchMolecular MedicineOsteoarthritibusinessmedicine.drugCellular and molecular life sciences : CMLS
researchProduct

Chondroprotective effects of the combination chondroitin sulfate-glucosamine in a model of osteoarthritis induced by anterior cruciate ligament trans…

2016

[EN] Context: The efficacy of the combination chondroitin sulfate-glucosamine (CS-GlcN) in the treatment of knee osteoarthritis (OA) has been suggested in recent clinical studies. In vitro reports have also suggested anti-inflammatory and anti-resorptive effects of this combination. Objective: The aim of this study was to characterize the effects of CS-GlcN on joint degradation in vivo including the assessment of inflammation and bone metabolism in a model of OA. Materials and methods: We have used the OA model induced by anterior cruciate ligament transection (ACLT) in ovariectomised rats. CS-GlcN was administered daily (oral gavage) from week 0 until week 12 after ovariectomy at the dose …

0301 basic medicineCartilage Articularmedicine.medical_specialtyAnterior cruciate ligamentOvariectomyType II collagenOsteoarthritisProtective AgentsBone and BonesBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOsteoprotegerinGlucosamineInternal medicineOsteoarthritisMedicineAnimalsChondroitin sulfateAnterior cruciate ligament transectionAnterior Cruciate LigamentRats Wistar030203 arthritis & rheumatologyPharmacologyGlucosaminebusiness.industryCartilageAnterior Cruciate Ligament InjuriesChondroitin SulfatesGeneral MedicineX-Ray MicrotomographyOsteoarthritis Kneemedicine.diseaseChondroitin sulfate-glucosamine Ovariectomised ratscarbohydrates (lipids)Disease Models Animal030104 developmental biologymedicine.anatomical_structureEndocrinologychemistryDrug Therapy CombinationFemaleJointsInflammation MediatorsbusinessBiomarkersModel
researchProduct

Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis.

2017

In the last decade the role of environmental factors as modulators of disease activity and progression has received increasing attention. In contrast to classical environmental modulators such as exposure to sun-light or fine dust pollution, nutrition is an ideal tool for a personalized human intervention. Various studies demonstrate a key role of dietary factors in autoimmune diseases including Inflammatory Bowel Disease (IBD), rheumatoid arthritis or inflammatory central nervous system (CNS) diseases such as Multiple Sclerosis (MS). In this review we discuss the connection between diet and inflammatory processes via the gut–CNS-axis. This axis describes a bi-directional communication syst…

0301 basic medicineCentral Nervous SystemMultiple SclerosisCentral nervous systemInflammationReviewBiologyInflammatory bowel diseaseModels BiologicalCatalysisInorganic ChemistryDisease activitylcsh:Chemistry03 medical and health sciencesImmune systemmedicinemicrobiotaAnimalsHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyInflammationMultiple sclerosisOrganic ChemistryGeneral Medicinemedicine.diseaseComputer Science ApplicationsGastrointestinal Tractgut–CNS-axisimmune system030104 developmental biologymedicine.anatomical_structurenutritionlcsh:Biology (General)lcsh:QD1-999Rheumatoid arthritisAdjunctive treatmentImmunologymedicine.symptomInternational journal of molecular sciences
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis

2018

Autoimmune rheumatic diseases are characterised by an abnormal immune system response, complement activation, cytokines dysregulation and inflammation. In last years, despite many progresses in managing these patients, it has been shown that clinical remission is reached in less than 50% of patients and a personalised and tailored therapeutic approach is still lacking resulting in a significant gap between guidelines and real-world practice. In this context, the need for biomarkers facilitating early diagnosis and profiling those individuals at the highest risk for a poor outcome has become of crucial interest. A biomarker generally refers to a measured characteristic which may be used as a…

0301 basic medicineEvidence-based practiceImmunologyInflammationGuidelines as TopicSystemic lupus erythematosuBioinformaticsAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis;Autoimmune DiseaseAutoimmune DiseasesRheumatic Disease03 medical and health sciencesTherapeutic approachSystemic sclerosiEconomica0302 clinical medicineImmune systemSystemic lupus erythematosusAntiphospholipid syndromeEarly DiagnosiRheumatic DiseasesAntiphospholipid syndromemedicineImmunology and AllergyHumansRheumatoid arthritisRheumatoid arthritiAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis030203 arthritis & rheumatologySpondyloarthritidebusiness.industryBiomarkermedicine.diseaseClinical diseaseSjögren syndromeAntiphospholipid syndrome; Biomarker; Rheumatoid arthritis; Sjögren syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Autoimmune Diseases; Biomarkers; Early Diagnosis; Evidence-Based Practice; Guidelines as Topic; Humans; Rheumatic Diseases; Immunology and Allergy; ImmunologySettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisRheumatoid arthritisEvidence-Based PracticeBiomarker (medicine)SpondyloarthritidesSystemic sclerosismedicine.symptombusinessBiomarkersHuman
researchProduct

Ectopic expression of CXCL13, BAFF, APRIL and LT-ß is associated with artery tertiary lymphoid organs in giant cell arteritis

2016

ObjectivesTo investigate whether artery tertiary lymphoid organs (ATLOs) are present in giant cell arteritis (GCA) and that their formation is associated with the ectopic expression of constitutive lymphoid tissue-homing chemokines.MethodsReverse transcriptase PCR, immunohistochemical and immunofluorescence analysis were used to determine the presence of ectopic ATLOs in GCA and the expression of chemokines/chemokine receptors and cytokines involved in lymphoneogenesis in the temporal artery samples obtained from 50 patients with GCA and 30 controls. The presence of lymphatic conduits, of follicular dendritic cells (FDCs) precursors and lymphoid tissue inducer cells was also investigated. F…

0301 basic medicineGenetics and Molecular Biology (all)ChemokineChemokines; Cytokines; Giant Cell Arteritis; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all); Immunology and AllergyHigh endothelial venulesImmunologyBiologyBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesChemokine receptor0302 clinical medicineRheumatologyChemokines; Cytokines; Giant Cell ArteritisImmunology and AllergyCXCL13B-cell activating factorCytokineGiant Cell Arteriti030203 arthritis & rheumatologyBiochemistry Genetics and Molecular Biology (all)Follicular dendritic cellsSettore MED/16 - Reumatologia030104 developmental biologyLymphatic systemChemokineImmunologybiology.proteinEctopic expression
researchProduct

Clinical efficacy of α4 integrin block with natalizumab in ankylosing spondylitis

2016

We describe the impact of α4-β1/7 blockade with natalizumab, a recombinant humanised immunoglobulin (Ig) G4κ monoclonal antibody (mAb) targeted to the α4 subunit of the α4β1 and α4β7 integrins, on the gut and spine inflammation in a patient with ankylosing spondylitis (AS) who developed multiple sclerosis after treatment with tumour necrosis factor (TNF)-blocking agents. A 45-year-old man with human leucocyte antigen (HLA)-B27-positive AS was admitted in January 2007. He had been diagnosed with AS 4 years earlier based on the presence of inflammatory back pain, peripheral arthritis, radiographic bilateral grade 2 sacroiliitis, HLA-B27 positivity. At that time, he had evidence of chronic int…

0301 basic medicineGenetics and Molecular Biology (all)medicine.drug_classImmunologyHuman leukocyte antigenMonoclonal antibodyBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineNatalizumabRheumatologymedicineAdalimumabImmunology and Allergy030203 arthritis & rheumatologyInflammationAnkylosing spondylitisBiochemistry Genetics and Molecular Biology (all)business.industryMultiple sclerosisMedicine (all)Sacroiliitismedicine.diseaseTreatmentSettore MED/16 - Reumatologia030104 developmental biologyImmunologyTumor necrosis factor alphaSpondyloarthritibusinessmedicine.drug
researchProduct

Response to: 'Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries' by Graver et al

2017

We thank Graver  et al 1 for their interest in our recently published article on artery tertiary lymphoid organs (ATLOs) in giant cell arteritis (GCA).2 The authors stained temporal artery biopsies of 21 biopsy-proven GCA patients (71% female, mean duration of disease of 2.3±0.9 months) that fulfilled the 1990 American College of Rheumatology classification criteria with anti-CD20 and anti-CD3 antibodies. On the basis of this experimental approach, they confirmed the presence of ATLOs only in the adventitia of inflamed arteries of GCA patients and not in the media as demonstrated in our study. This statement, however, is not supported in our opinion by the experimental approach chosen …

0301 basic medicineGenetics and Molecular Biology (all)medicine.medical_specialtyPathologyBiopsyGiant Cell ArteritisImmunologyDisease Activity; Giant Cell Arteritis; TreatmentBiochemistryGeneral Biochemistry Genetics and Molecular BiologyDisease activity03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineAdventitiamedicineHumansImmunology and AllergyDisease ActivityGiant Cell Arteriti030203 arthritis & rheumatologyBiochemistry Genetics and Molecular Biology (all)business.industryArteriesmedicine.diseaseRheumatologyTemporal ArteriesTreatmentGiant cell arteritis030104 developmental biologymedicine.anatomical_structureLymphatic systemcardiovascular systemTemporal arterybusinessArtery
researchProduct

Primary sjogren syndrome: Focus on innate immune cells and inflammation

2020

Primary Sjogren Syndrome (pSS) is a complex, multifactorial rheumatic disease that mainly targets salivary and lacrimal glands, inducing epithelitis. The cause behind the autoimmunity outbreak in pSS is still elusive; however, it seems related to an aberrant reaction to exogenous triggers such as viruses, combined with individual genetic pre-disposition. For a long time, autoantibodies were considered as the hallmarks of this disease; however, more recently the complex interplay between innate and adaptive immunity as well as the consequent inflammatory process have emerged as the main mechanisms of pSS pathogenesis. The present review will focus on innate cells and on the principal mechani…

0301 basic medicineImmunologyinnate lymphoid cellslcsh:MedicineIFN signatureInflammationDiseaseReviewmedicine.disease_causeAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicinestomatognathic systemDrug DiscoverymedicineInnate lymphoid cellPharmacology (medical)Sjogren syndromeCytokine030203 arthritis & rheumatologyPharmacologyInflammationInnate immunityInnate immune systemSjogren syndrome.business.industryInnate lymphoid celllcsh:RAutoantibodyAcquired immune systemcytokinesstomatognathic diseases030104 developmental biologyInfectious DiseasesImmunologymedicine.symptombusiness
researchProduct